Reinventing primaquine for endemic malaria

Expert Opinion on Emerging Drugs

Volumn 17, Issue 4, 2012, Pages 439-444

  Baird, John Kevin ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

G6PD deficiency; Hemolytic toxicity; Malaria elimination; Primaquine

Indexed keywords

CHLOROQUINE; ISOPENTAQUINE; MEPACRINE; PAMAQUINE; PRIMAQUINE; QUININE;

BLOOD TOXICITY; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; GAMETOCYTE; GENE MUTATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; MALARIA; MALARIA FALCIPARUM; PARASITE TRANSMISSION; PLASMODIUM VIVAX MALARIA; PRACTICE GUIDELINE; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDEMIC DISEASES; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMANS; MALARIA; PRIMAQUINE; RECURRENCE;

EID: 84870469368     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.720252     Document Type: Review

References (29)

1. Baird JK. Elimination therapy for the endemic malarias. Curr Infect Dis Rep 2012;14:227-37
2. Shannon JA. Chemotherapy in malaria. Bull NY Acad Med 1946;22:345-57
3. Neill US. From branch to bedside: Youyou Tu is awarded the 2011 Lasker-DeBakey Clinical Medical Research Award fro discovering artemisinin as a treatment for malaria. J Clin Invest 2011;12(10):3768-73
4. Office of the Surgeon General. The drug treatment of malaria, suppressive and clinical. circular letter No.153. JAMA 1943;123:205-8
5. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008;111:16-24
6. Alving AS, Johnson CF, Tarlov AR, et al. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the chesson strain of plasmodium vivax by intermittent regimens of drug administration. A preliminary report. Bull WHO 1960;22:621-31
7. Marks PA, Gross RT. Erythrocytic glucose-6-phosphate dehydrogenase deficiency: evidence of differences between Negroes and Caucasians with respect to this genetically determined trait. J Clin Invest 1959;38:2253-5
8. Baird JK, Surjadjaja C. Consideration of ethics of primaquine therapy against malaria transmission. Trends Parasitol 2011;27:11-16
9. Barrett O Jr, Skrzypek G, Datel W, Goldstein JD. Malaria imported to the United States from Vietnam. Chemoprophylaxis evaluated in returning soldiers. Am J Trop Med Hyg 1969;18:495-9
10. Rieckmann KH, McNamara JV, Frischer H, et al. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyramethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull WHO 1968;38:625-32
11. Peters W. Chemotherapy and drug resistance in malaria. 2nd edition Volume 2 Academic Press; London: 1987. p. 579-80; 1100pp
12. Burgoine KL, Bancone G, Nosten F. The reality of using primaquine. Malaria J 2010;9:376
13. Ziai M, Amirhakimi GH, Rienhold JG, et al. Malaria prophylaxis and treatment in G6PD deficiency: an observation on the toxicity of primaquine and chloroquine. Clin Pediatr (Phila) 1967;6:242-3
14. Reeve PE, Toaliu H, Kaneko A, et al. Acute intravascular haemolysis in vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency. Trans Roy Soc Trop Med Hyg 1992;95:349-51
15. Abeyaratne KP, Halpe NL. Sensitivity to primaquine in ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. Ceylon Med J 1968;13:134-8
16. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64-74
17. George GN, Sears DA, McCurdy PR, Conrad ME. Primaquine sensitivity in caucasians: hemolytic reactions induced by primaquine in G6PD-deficient subjects. J Lab Clin Med 1967;70:80-93
18. Pannacciulli I, Tizianello A, Ajmar F, Salvidio E. The course of experimentally induced hemolytic anemia in a primaquine-sensitive caucasian. Blood 1965;25:92-5
19. Salvidio E, Pannacciulli I, Tizianello A, Ajmar F. Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. New Engl J Med 1967;276:1339-44
20. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull WHO 1981;59(3):391-5
21. Burgess RW, Bray RS. Effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. Bull WHO 1961;24:451-6
22. Rieckmann KH, McNamara JV, Kass L, Powell RD. Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Mil Med 1969; 134(10): 805-19
23. Baird JK. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 2011;55:1827-30
24. Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1955;46:301-6
25. Schmidt LH. Enhancement of the curative action of primaquine by concomitant administration of mirinamycin. Antimicrob Agents Chemother 1985;27:151-7
26. Milhous W. Development of new drugs for chemophrophylaxis of malaria. Bull Soc Pathol Exot 2001;94:149-51
27. Nasveld PE, Edstein MD, Reid M, et al. The Tafenoquine Study Team. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in non-immune subjects. Antimicrob Agents Chemother 2010;54:792-8
28. Dow GS, Gettayacamin M, Hansukjariya P, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected rhesus monkeys (Macaca mulatta). Malaria J 2011;10:212
29. Alving AS, Eichelberger L, Arnold J, Edgcomb J. The clinical testing of antimalarial drugs at Stateville Penitentiary. Semi-Annual Report 1948-49. NIH Malaria Report NO.87. USPHS Antimalarial Grant No.RG 198. 1 January 1949.